Clinical trials: Copper
Contraception
A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)
The purpose of this study is to demonstrate that a new device inserter leads to successful and safe insertion of Paragard® IUS, comparable to the currently approved IUS inserter, in females of reproductive potential.
- Trial name
- NCT05309694
- Testing
- Paragard® T380A Intrauterine Copper Contraceptive with New Inserter
- Where
- 8 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- CooperSurgical Inc.
Wilson Disease
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications.
- Trial name
- NCT02763215
- Testing
- Standard of Care Medications
- Where
- 10 sites in United States, Austria and 3 more
- Volunteers
- 64 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy
Copper Balance in Healthy Participants Administered ALXN1840
The study will assess the change from baseline in mean daily copper balance in healthy participants with repeat-dose administrations of ALXN1840 over 2 weeks.
- Trial name
- NCT04594252
- Testing
- ALXN1840
- Where
- United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Recurrent Glioblastoma
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.
- Trial name
- NCT03034135
- Testing
- Disulfiram/Copper, Temozolomide (TMZ)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cantex Pharmaceuticals
Neuroendocrine Tumors
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.
- Trial name
- NCT03673943
- Testing
- 64Cu-DOTATATE
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Radiomedix, Inc.
Metastasis From Malignant Tumor of Prostate (Disorder)
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.
- Trial name
- NCT05653856
- Testing
- 64Cu-PSMA I&T
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Curium US LLC
Dermatitis, Eczematous
Clinical Evaluation of Metal Panel Allergens: Dose Response Study
48-hour application of metal allergen patches to test for potential allergic responses.
- Trial name
- NCT02615249
- Testing
- Metal Allergen Epicutaneous Patch
- Where
- 8 sites in United States, Germany and 4 more
- Volunteers
- 122 people
- Sponsor
- Allerderm
Wilson Disease
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation…
- Trial name
- NCT03403205
- Testing
- ALXN1840, SoC Therapy
- Where
- 56 sites in United States, Australia and 20 more
- Volunteers
- 214 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Wilson Disease
Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at…
- Trial name
- NCT04422431
- Testing
- Bis-Choline Tetrathiomolybdate
- Where
- 12 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuralgia, Myalgia
Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain
Male and female participants were selected based on chronic neuromuscular pain. Patients were instructed to take two doses of the placebo or cuprous nicotinic acid chelate Cunermusmir twice a day for 28 days.
- Trial name
- NCT04737278
- Testing
- Cunermuspir
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Mitosynergy LLC
Contraception
Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
Prospective, multi-center, single-arm, open-label, Phase II clinical study to evaluate the effectiveness, device placement, safety, and tolerability of VeraCept to support commencing a Phase III Clinical Study
- Trial name
- NCT02446821
- Testing
- VeraCept
- Where
- 12 sites in United States
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Sebela Women's Health Inc.
Contraception
A Study to Evaluate the Safety and Initial Efficacy of a Novel Intrauterine Device
Current intrauterine devices (IUD) pose such risks as uterine perforation during insertion, malposition and expulsion. The investigated device, the IUB(tm) SCu300A is an IUD which is inserted in a similar fashion into the uterus…
- Trial name
- NCT01590563
- Testing
- IUD
- Where
- Hungary
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ocon Medical Ltd.
Wilson Disease
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
- Trial name
- NCT04573309
- Testing
- ALXN1840
- Where
- 3 sites in United States, New Zealand and 1 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.